Christoph Hubertus Ladel

USPTO Granted Patents = 11 (Patent Applications = 10)

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 10 (Patent Applications = 8)

Average Co-Inventor Count = 3.7

ph-index = 3

Forward Citations = 31(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12383603 - Markers useful in enrichment strategies for the treatment of osteoarthritis (2025-08-12),

2. 12332251 - Metabolic biomarkers for predicting responsiveness to FGF-18 compound (2025-06-17),

3. 12129308 - MMP13 binding immunoglobulins (2024-10-29),

4. 11813307 - Polypeptides binding ADAMTS5, MMP13 and aggrecan (2023-11-14),

5. 11603401 - Aggrecan binding immunoglobulins (2023-03-14),

6. 11513128 - Metabolic biomarkers for predicting responsiveness to FGF-18 compound (2022-11-29),

7. 11467169 - Inflammatory biomarkers for predicting responsiveness to FGF-18 compound (2022-10-11),

8. 10221456 - Genetic markers for predicting responsiveness to FPG-18 compound (2019-03-05),

9. 10086112 - Implant comprising FGF-18 (2018-10-02),

10. 9889179 - FGF-18 compound dosing regimen (2018-02-13),

11. 9724388 - FGF-18 compound dosing regimen (2017-08-08),

Title: Christoph Hubertus Ladel: Transforming Industries with Innovative Polypeptides

Introduction:

Christoph Hubertus Ladel, a pioneering inventor based in Darmstadt, Germany, has made significant strides in the field of biotechnology with his groundbreaking inventions.

Latest Patents:

Ladel's latest patents revolve around polypeptides binding ADAMTS5, MMP13, and aggrecan. These inventions include constructs comprising immunoglobulins that target specific proteins, with applications in prophylactic and therapeutic purposes.

Career Highlights:

With a total of 8 patents to his name, Ladel has showcased his expertise in developing novel biotechnological solutions. His work demonstrates a deep understanding of immunoglobulins and their potential in the pharmaceutical industry.

Collaborations:

Ladel has collaborated with esteemed companies such as Merck Patent GmbH and Ablynx N.V. during his career. Working alongside coworkers like Hans Guehring and Anne-Christine Bay-Jensen has allowed him to bring his innovative ideas to fruition.

Conclusion:

Christoph Hubertus Ladel stands out as a visionary inventor whose dedication to pushing the boundaries of innovation has the potential to transform industries and enhance the quality of life for people worldwide. His contributions in the field of biotechnology signify a bright future for advancements in healthcare and pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.